Cookie Hinweis

Wir verwenden Cookies, um Ihnen ein optimales Webseiten-Erlebnis zu bieten. Dazu zählen Cookies, die für den Betrieb der Seite notwendig sind, sowie solche, die lediglich zu anonymen Statistikzwecken, für Komforteinstellungen oder zur Anzeige personalisierter Inhalte genutzt werden. Sie können selbst entscheiden, welche Kategorien Sie zulassen möchten. Bitte beachten Sie, dass auf Basis Ihrer Einstellungen womöglich nicht mehr alle Funktionalitäten der Seite zur Verfügung stehen. Weitere Informationen finden Sie in unseren Datenschutzhinweisen .

Essentiell

Diese Cookies sind für die Funktionalität unserer Website erforderlich und können nicht deaktiviert werden.

Name Webedition CMS
Zweck Dieses Cookie wird vom CMS (Content Management System) Webedition für die unverwechselbare Identifizierung eines Anwenders gesetzt. Es bietet dem Anwender bessere Bedienerführung, z.B. Speicherung von Sucheinstellungen oder Formulardaten. Typischerweise wird dieses Cookie beim Schließen des Browsers gelöscht.
Name econda
Zweck Session-Cookie für die Webanalyse Software econda. Diese läuft im Modus „Anonymisiertes Messen“.
Statistik

Diese Cookies helfen uns zu verstehen, wie Besucher mit unserer Webseite interagieren, indem Informationen anonym gesammelt und analysiert werden. Je nach Tool werden ein oder mehrere Cookies des Anbieters gesetzt.

Name econda
Zweck Measure with Visitor Cookie emos_jcvid
Externe Medien

Inhalte von externen Medienplattformen werden standardmäßig blockiert. Wenn Cookies von externen Medien akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Zustimmung mehr.

Name YouTube
Zweck Zeige YouTube Inhalte
Name Twitter
Zweck Twitter Feeds aktivieren

Publications 2016

Akram I.G., Georges R., Hielscher T., Adwan H., Berger M.R.: The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis. Tumor Biol. 37 (2) 2461-2471, 2016.

Balss J., Thiede C., Bochtler T., Okun J.G., Saadati M., Benner A., Pusch S., Ehninger G., Schaich M., Ho A.D., von Deimling A., Krämer A., Heilig C.E.: Pretreatment D-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. Leukem. 30 782-788, 2016.

Bärtsch M.A., Schlenzka J., Mai E.K., Merz M., Hillengass J., Raab M.S., Hose D., Wuchter P., Ho A.D., Jauch A., Hielscher T., Kunz C., Luntz S., Klein S., Schmidt-Wolf I.G., Görner M., Schmidt-Hieber M., Reimer P., Graeven U., Fenk R., Salwender H., Scheid C., Nogai A., Hänel M., Lindemann H.W., Martin H., Noppeney R., Weisel K., Goldschmidt H.: Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC Cancer 16 290, 2016.

Betge J., Barat A., Murphy V., Hielscher T., van Grieken N.C., Belle S., Zhan T., Härtel N., Kripp M., Bacon O., Cordes M., Kay E.W., Verheul H.M., Neerincx M., Hennessy B., Hofheinz R.D., Gaiser T., Yistra B., Prehn J.H., Lambrechts D., Byrne A.T., Ebert M.P., Schulte N.: Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. Digestion 94 (3) 129-137, 2016.

Bochtler T., Hegenbart U., Kunz C., Benner A., Kimmich C., Seckinger A., Hose D., Goldschmidt H., Granzow M., Dreger P., Ho A.D., Jauch A., Schönland S.O.: Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood 128 (4) 594-602, 2016.

Burth S., Kickingereder P., Eidel O., Tichy D., Bonekamp D., Weberling L., Wick A., Löw S., Hertenstein A., Nowosielski M., Schlemmer H.P., Wick W., Bendszus M., Radbruch A.: Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. Neuro-Oncol. 18 (12) 1673-1679, 2016.

Chessa F., Hielscher T., Mathow D., Gröne H.J., Popovic Z.V.: Transcriptional profiling of dendritic cells matured in different osmolarities. Genomics Data 7 64-66, 2016.

Chessa F., Mathhow D., Wang S., Hielscher T., Atzberger A., Porubsky S., Gretz N., Burgdorf S., Gröne H.J., Popovic Z.V.: The renal microenvironment modifies dendritic cell phenotype. Kidney Int. 89 (1) 82-94, 2016.

Cieciera M., Kratochwil C., Moltz J., Kauczor H.U., Holland-Letz T., Choyke P., Mier W., Haberkorn U., Giesel F.L.: Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC. Diagn.Interv.Radiol. 22 (3) 201-206, 2016.

Dick J., Lang N., Slynko A., Kopp-Schneider A., Schulz C., Dimitrakopoulou-Strauss A., Enk A.H., Hassel J.C.: Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. Immunotherapy 8 (9) 1033-1044, 2016.

Dubash T.D., Hoffmann C.M., Oppel F., Giessler K.M., Bergmann S., Dieter S.M., Hüllein J., Zenz T., Herbst F., Scholl C., Weichert W., Werft W., Benner A., Schmidt M., Schneider M., Glimm H., Ball C.R.: Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells. Cancer Lett. 371 (2) 326-333, 2016.

Echterdiek F., Janikovits J., Staffa L., Müller M., Lahrmann B., Frühschütz M., Hartog B., Nelius N., Benner A., Tariverdian M., von Knebel-Döberitz M., Grabe N., Kloor M.: Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. OncoImmunol. 5 (2) e1075692, 2016.

Fabian J., Opitz D., Althoff K., Lodrini M., Hero B., Volland R., Beckers A., Preter K., Decock A., Patil N., Abba M., Kopp-Schneider A., Astrahantseff K., Wünschel J., Pfeil S., Ercu M., Künkele A., Hu J., Thole T., Schweizer L., Mechtersheimer G., Carter D., Cheung BB., Popanda O., Deimling A.v., Koster J., Versteeg R., Eggert A., Witt O., Schulte J.H., Deubzer H.E.: MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget (epub) , 2016.

Federico G., Meister M., Mathow D., Heine G.H., Moldenhauer G., Popovic Z.V., Nordström V., Kopp-Schneider A., Hielscher T., Nelson P.J., Schaefer F., Porubsky S., Fliser D., Arnold B., Gröne H.J.: Tubular Dickkopf-3 promotes the development of renal atrophy and fibrosis. JCI Insight 1 (1) e84916, 2016.

Fellenberg J., Sähr H., Kunz P., Zhao Z., Liu L., Tichy D., Herr I.: Restoration of miR-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6. Cancer Lett. 371 (1) 134-141, 2016.

Fernando R.N., Chaudhari U., Escher S.E., Hengstler J.G., Hescheler J., Jennings P., Keun H.C., Kleinjans J.C., Kolde R., Kollipara L., Kopp-Schneider A., Limonciel A., Nemade H., Nguemo F., Peterson H., Prieto P., Rodrigues R.M., Sachinidis A., Schäfer C., Sickmann A., Spitkovsky D., Stöber R., van Breda S.G., van de Water B., Vivier M., Zahedi R.P., Vinken M., Rogiers V.: "Watching the Detectives" report of the general assembly of the EU project DETECTIVE Brussels, 24-25 November 2015. Arch.Toxicol. 90 (6) 1529-1539, 2016.

Filarsky K., Garding A., Becker N., Wolf C., Zucknick M., Claus R., Weichenhan D., Plass C., Döhner H., Stilgenbauer S., Lichter P., Mertens D.: Kruppel-like factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling. Haematologica 101 (6) E249-E253, 2016.

Flechsig P., Choyke P., Kratochwil C., Warth A., Antoch G., Holland-Letz T., Rath D., Eichwald V., Huber P.E., Kauczor H.U., Haberkorn U., Giesel F.L.: Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer. Diagn.Interv.Radiol. 22 (1) 35-39, 2016.

Freitag M.T., Radtke J.P., Hadaschik B.A., Kopp-Schneider A., Eder M., Kopka K., Haberkorn U., Röthke M., Schlemmer H.P., Afshar-Oromieh A.: Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur.J.Nucl.Med.Mol.Imag. 43 (1) 70-83, 2016.

Gdynia G., Sauer S.W., Kopitz J., Fuchs D., Duglova K., Ruppert T., Miller M., Pahl J., Cerwenka A., Enders M., Mairbäul H., Kaminski M.M., Penzel R., Zhang C., Fuller J.C., Wade R.C., Benner A., Chang-Claude J., Brenner H., Hoffmeister M., Zentgraf H., Schirmacher P., Roth W.: The HMGB1 protein induces a metabolic type of tumour cell death by blocking aerobic respiration. Nat.Commun. 7 (Article No. 10764) , 2016.

Giesel F.L., Sterzing F., Schlemmer H.P., Holland-Letz T., Mier W., Rius M., Afshar-Oromieh A., Kopka K., Debus J., Haberkorn U., Kratochwil C.: Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur.J.Nucl.Med.Mol.Imag. 43 (8) 1400-1406, 2016.

Habl G., Uhl M., Katayama S., Kessel K.A., Hatiboglu G., Hadaschik B., Edler L., Tichy D., Ellerbrock M., Haberer T., Wolf M.B., Schlemmer H.P., Debus J., Herfarth K.: Acute toxicity and quality of life in patients with prostate cancer treated with protons or carbon ions in a prospective randomized phase II study -The IPI trial. Int.J.Radiat.Oncol.Biol.Phys. 95 (1) 435-443, 2016.

Halama N., Zörnig I., Berthel A., Kahlert C., Klupp F., Suarez-Carmona M., Sütterlin T., Brand K., Krauss J., Lasitschka F., Lerchi T., Luckner-Minden C., Ulrich A., Koch M., Weitz J., Schneider M., Büchler M.W., Zitvogel L., Herrmann T., Benner A., Kunz C., Lücke S., Springfeld C., Grabe N., Falk C.S., Jäger D.: Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell 29 (4) 587-601, 2016.

Hanna B.S., McClanathan F., Yazdanparast H., Zaborsky N., Kalter V., Rößner P.M., Benner A., Dürr C., Egle A., Gribben J.G., Lichter P., Seiffert M.: Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukem. 30 570-579, 2016.

Hatiboglu G., Teber D., Tichy D., Pahernik S., Hadaschik B., Nyarangi-Dix J., Hohenfellner M.: Predictive factors for immediate continence after radical prostatectomy. World J.Urol. 34 (1) 113-120, 2016.

Heim S., Sill M., Jones D.T., Vasiljevic A., Jouvet A., Fevre-Montange M., Wesseling P., Beschorner R., Mittelbronn M., Kohlhof P., Hovestadt V., Johann P., Kool M., Pajtler K.W., Korshunov A., Ruland V., Sperveslage J., Thomas.C., Witt H., von Deimling A., Paulus W., Pfister S.M., Capper D., Hasselblatt M.: Papillary tumor of the pineal region: a distinct molecular entity. Brain Pathol. 26 (2) 199-205, 2016.

Henrich K.O., Bender S., Saadati M., Dreidax D., Gartlgruber M., Shao C., Herrmann C., Wiesenfarth M., Parzonka M., Wehmann L., Fischer M., Duffy D.J., Bell E., Torkov A., Schmezer P., Plass C., Höfer T., Benner A., Pfister S.M., Westermann F.: Integrative genome-scale analysis identifies epigenetic mechanisms of transcriptional deregulation in unfavorable neuroblastomas. Cancer Res. 76 (18) 5523-5537, 2016.

Hertenstein A., Hielscher T., Menn O., Wiestler B., Winkler F., Platten M., Wick W., Wick A.: Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. J.Neuro-Oncol. 129 (3) 533-539, 2016.

Hieke S., Benner A., Schlenk R.F., Schumacher M., Bullinger L., Binder H.: Identifying prognostic SNPs in clinical cohorts: complementing univariate analyses by resampling and multivariable modeling. PLoS_ONE 11 (5) e0155226, 2016.

Hieke S., Benner A., Schlenk R.F., Schumacher M., Bullinger L., Binder H.: Integrating multiple molecular sources into a clinical risk prediction signature by extracting complementary information. BMC Bioinformatics 17 (1) 327, 2016.

Hillengass J., Ritsch J., Merz M., Wagner B., Kunz C., Hielscher T., Laue H., Bäuerle T., Zechmann C.M., Ho A.D., Schlemmer H.P., Goldschmidt H., Möhler T.M., Delorme S.: Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma. Br.J.Haematol. 174 (1) 127-135, 2016.

Hofner B., Schmid M., Edler L.: Reproducible research in statistics: A review and guidelines for the Biometrical Journal. Biometr.J. 58 (2) 416-427, 2016.

Hölsken A., Sill M., Merkle J., Schweizer L., Buchfelder M., Flitsch J., Fahlbusch R., Metzler M., Kool M., Pfister S.M., Deimling A.v., Capper D., Jones D.T., Buslei R.: Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol.Commun. 4 (1) 20, 2016.

Hütter-Krönke M.L., Benner A., Döhner K., Krauter J., Weber D., Mössner M., Köhne C.H., Horst H.A., Schmidt-Wolf I.G., Rummel M., Götze K., Koller E., Petzer A.L., Salwender H., Fiedler W., Kirchen H., Haase D., Kremers S., Theobald M., Matzdorff A.C., Ganser A., Döhner H., Schlenk R.F.: Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. Haematologica 101 (7) 839-845, 2016.

Josupeit R., Bender S., Kern S., Leuchs B., Hielscher T., Herold-Mende C., Schlehofer J.R., Dinsart C., Witt O., Rommelaere J., Lacroix J.: Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1. Viruses 8 (5) E138, 2016.

Kap E.J., Seibold P., Scherer D., Habermann N., Balavarca Y., Jansen L., Zucknick M., Becker N., Hofmeister M., Ulrich A., Benner A., Ulrich C.M., Burwinkel B., Brenner H., Chang-Claude J.: SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients. Int.J.Cancer 138 (12) 2993-3001, 2016.

Kayser S., Benner A., Thiede C., Martens U., Huber J., Stadtherr P., Janssen J.W., Röllig C., Uppenkamp M.J., Bochtler T., Hegenbart U., Ehninger G., Ho A.D., Dreger P., Krämer A.: Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Blood Cancer J. 6 (7) e449, 2016.

Kickingereder P., Bonekamp D., Nowosielski M., Kratz A., Sill M., Burth S., Wick A., Eidel O., Schlemmer H.P., Radbruch A., Debus J., Herold-Mende C., Unterberg A., Jones D., Pfister S., Wick W., Deimling A.v., Bendszus M., Capper D.: Radiogenomics of glioblastoma: Machine learning-based classification of molecular characteristics by using multiparametric and multiregional MR imaging features. Radiology 281 (3) 907-918, 2016.

Kickingereder P., Götz M., Muschelli J., Wick A., Neuberger U., Shinohara R.T., Sill M., Nowosielski M., Schlemmer H.P., Radbruch A., Wick W., Bendszus M., Maier-Hein K.H., Bonekamp D.: Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response. Clin.Cancer Res. 22 (23) 5765-5771, 2016.

Konotop G., Bausch E., Nagai T., Turchinovich A., Becker N., Benner A., Boutros M., Mizuno K., Krämer A., Raab M.S.: Pharmacological inhibition of centrosome clustering by slingshot-mediated cofilin activation and actin cortex destabilization. Cancer Res. 76 (22) 6690-6700, 2016.

Kostareli E., Hielscher T., Zucknick M., Baboci L., Wichmann G., Holzinger D., Mücke O., Pawlita M., Del Mistro A., Boscolo-Rizzo P., Da Mosto M.C., Tirelli G., Plinkert P., Dietz A., Plass C., Weichenhan D., Hess J.: Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients. Epigenetics 11 (1) 61-73, 2016.

König M., Hagens C.v., Hoth S., Baumann I., Walter-Sack I., Edler L., Sertel S.: Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study. Cancer Chemother.Pharmacol. 77 (2) 413-427, 2016.

Lim H.J., Weinheimer O., Wielpütz M.O., Dinkel J., Hielscher T., Gompelmann D., Kauczor H.U., Heussel C.P.: Fully automated pulmonary lobar segmentation: influence of different prototype software programs onto quantitative evaluation of chronic obstructive lung disease. PLoS_ONE 11 (3) e0151498, 2016.

Löffler H., Pfarr N., Kriegsmann M., Endris V., Hielscher T., Lohneis P., Folprecht G., Stenzinger A., Dietel M., Weichert W., Krämer A.: Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget 7 (28) 44322-44329, 2016.

Madhavan D., Peng C., Wallwiener M., Zucknick M., Nees J., Schott S., Rudolph A., Riethdorf S., Trumpp A., Pantel K., Sohn C., Chang-Claude J., Schneeweiss A., Burwinkel B.: Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. Carcinogen. 37 (5) 461-470, 2016.

Mai E.K., Benner A., Bertsch U., Brossart P., Hänel A., Kunzmann V., Naumann R., Neben K., Egerer G., Ho A.D., Hillengass J., Raab M.S., Neubauer A., Peyn A., Ko Y.D., Peter N., Scheid C., Goldschmidt H.: Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br.J.Haematol. 173 (5) 731-741, 2016.

Mai E.K., Hielscher T., Kloth J.K., Merz M., Shah S., Hillengass M., Wagner B., Hose D., Raab M.S., Jauch A., Delorme S., Goldschmidt H., Weber M.A., Hillengass J.: Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology. Eur.Radiol. 26 (11) 3939-3946, 2016.

Merz M., Hielscher T., Seckinger A., Hose D., Mai E.K., Raab M.S., Goldschmidt H., Jauch A., Hillengass J.: Baseline characteristics, chromosomal alterations and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. Am.J.Hematol. 91 (11) E473-E477, 2016.

Merz M., Möhler M., Ritsch J., Bäuerle T., Zechmann C., Wagner B., Jauch A., Hose D., Kunz C., Hielscher T., Laue H., Goldschmidt H., Delorme S., Hillengass J.: Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study. Eur.Radiol. 26 (5) 1404-1411, 2016.

Merz M., Salwender H., Hänel M., Mai E.K., Bertsch U., Kunz C., Hielscher T., Blau I.W., Scheid C., Hose D., Seckinger A., Jauch A., Hillengass J., Raab M.S., Schurich B., Munder M., Brossart P., Gerecke C., Lindemann H.W., Zeis M., Weisel K., Dürig J., Goldschmidt H.: Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica 101 (12) e185-e187, 2016.

Mock A., Geisenberger C., Orlik C., Warta R., Schwager C., Jungk C., Dutruel C., Geiselhart A., Weichenhan D., Zucknick M., Nied A.K., Friauf S., Exner J., Capper D., Hartmann C., Lahrmann B., Grabe N., Debus J., Deimling A.v., Popanda O., Plass C., Unterberg A., Abdollahi A., Schmezer P., Herold-Mende C.: LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. Int.J.Cancer 139 (2) 424-432, 2016.

Noll E.M., Eisen C., Stenzinger A., Espinet E., Muckenhuber A., Klein C., Vogel V., Klaus B., Nadler W., Rösli C., Lutz C., Kulke M., Engelhardt J., Zickgraf F.M., Epsinosa O., Schlesner M., Jiang X., Kopp-Schneider A., Neuhaus P., Bahra M., Sinn B.V., Eils R., Giese N.A., Hackert T., Strobel O., Werner J., Büchler M.W., Weichert W., Trumpp A., Sprick M.R.: CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat.Med. 22 278-287, 2016.

Nwaeburu C.C., Bauer N., Zhao Z., Abukiwan A., Gladkich J., Benner A., Herr I.: Up-regulation of microRNA Let-7c by quercetin inhibits pancreatic cancer progression by activation of Numbl. Oncotarget 7 (36) 58367-58380, 2016.

Paco S., Hummel M., Pla V., Sumoy L., Aquado F.: Cyclic AMP signaling restricts activation and promotes maturation and antioxidant defenses in astrocytes. BMC Genomics 17 (1) 304, 2016.

Phillips E., Lang V., Bohlen J., Bethke F., Puccio L., Tichy D., Herold-Mende C., Hielscher T., Lichter P., Goidts V.: Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism. Int.J.Cancer 139 (8) 1776-1778, 2016.

Pickl J.M., Tichy D., Kuryshev V.Y., Tolstov Y., Falkenstein M., Schüler J., Reidenbach D., Hotz-Wagenblatt A., Kristiansen G., Roth W., Hadaschik B., Hohenfellner M., Dünsing S., Heckmann D., Sültmann H.: Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. Oncotarget 7 (37) 59589-59603, 2016.

Portier C.J., Armstrong B.K., Baguley B.C., Baur X., Belyaev I., Belle R., Belpoggi F., Biggeri A., Bosland M.C., Brucci P., Budnik L.T., Bugge M.D., Burns K., Calaf G.M., Carpenter D.O., Carpenter H.M., Lopez-Carillo L., Clapp R., Cocco P., Consonni D., Comba P., Craft E., Dalvie M.A., Davis D., Demers P.A., De Roos A.J., De Witt J., Forastiere F., Freedman J.H., Fritschi L., Gaus C., Gohlke J.M., Goldberg M., Greiser E., Hansen J., Hardell L., Hauptmann M., Huang W., Huff J., James M.O., Jameson C.W., Kortenkamp A., Kopp-Schneider A., Kromhout H., Larramendly M.L., Landrigan P.J., Lash L.H., Leszczynski D., Lynch C.F., Magnani C., Mandrioli D., Martin F.L., Merler E., Michelozzi P., Miligi L., Miller A.B., Mirabelli D., Mirer F.E., Naidoo S., Perry M.J., Petronio M.G., Pirastu R., Portier R.J., Ramos K.S., Robertson L.W., Rodriguez T., Röösli M., Ross M.K., Roy D., Rusyn I., Saldiva P., Sass J., Savolainen K., Scheepers P.T., Sergi C., Silbergeld E.K., Smith M.T., Stewart B.W., Sutton P., Tateo F., Terracini B., Thielmann H.W., Thomas D.B., Vainio H., Vena J.E., Vineis P., Weiderpass E., Weisenburger D.D., Woodruff T.J., Yorifuji T., Yu I.J., Zambon P., Zeeb H., Zhou S.F.: Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA). J.Epidemiol.Commun.Health 70 741-745, 2016.

Radujkovic A., Dietrich S., Andrulis M., Benner A., Longerich T., Pellagatti A., Nanda K., Giese T., Germing U., Baldus S., Boultwood J., Ho A.D., Dreger P., Luft T.: Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy. Int.J.Cancer 139 (6) 1402-1413, 2016.

Ramaswamy V., Hielscher T., Mack S.C., Lassaletta A., Lin T., Pajtler K.W., Jones D.T., Luu B., Cavalli F.M., Aldape K., Remke M., Mynarek M., Rutkowski S., Gururangan S., McLendon R.E., Lipp E.S., Dunham C., Hukin J., Eisenstat D.D., Fulton D., van Landeghem F.K., Santi M., van Veelen M.L., Van Meir E.G., Osuka S., Fan X., Muraszko K.M., Tirapelli D.P., Oba-Shinjo S.M., Marie S.K., Carlotti C.G., Lee J.Y., Rao A.A., Giannini C., Faria C.C., Nunes S., Mora J., Hamilton R.L., Hauser P., Jabado N., Petrecca K., Jung S., Massimi L., Zollo M., Cinalli G., Bognar L., Klekner A., Hortobagyi T., Leary S., Ermoian R.P., Olson J.M., Leonard J.R., Gardner C., Grajkowska W.A., Chambless L.B., Cain J., Eberhart C.G., Ahsan S., Massimino M., Giangaspero F., Buttarelli F.R., Packer R.J., Emery L., Yong W.H., Soto H., Liau L.M., Everson R., Grossbach A., Shalaby T., Grotzer M., Karajannis M.A., Zagzag D., Wheeler H., von Hoff K., Alsonso M.M., Tunon T., Schüller U., Zitterbart K., Sterba J., Chan J.A., Guzman M., Elbabaa S.K., Colman H., Dhall G., Fisher P.G., Fouladi M., Gajjar A., Goldman S., Hwang E., Kool M., Ladha H., Vera-Bolanos E., Wani K., Lieberman F., Mikkelsen T., Omuro A.M., Pollack I.F., Prados M., Robins H.I., Soffietti R., Wu J., Metellus P., Tabori U., Bartels U., Bouffet E., Hawkins C.E., Rutka J.T., Dirks P., Pfister S.M., Merchant T.E., Gilbert M.R., Armstrong T.S., Korshunov A., Ellison D.W., Taylor M.D.: Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis. J.Clin.Oncol. 34 (21) 2468-2477, 2016.

Rios-Tamayo R., Lupianez C.B., Campa D., Hielscher T., Weinhold N., Martinez-Lopez J., Jerez A., Landi S., Jamroziak K., Dumontet C., Watek M., Lesueur F., Reis R.M., Marques H., Jurczyszyn A., Vogel U., Buda G., Garcia-Sanz R., Orciuolo E., Petrini M., Vangsted A.J., Gemignani F., Försti A., Goldschmidt H., Hemminki K., Canzian F., Jurado M., Sainz J.: A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget 7 (37) 59029-59048, 2016.

Sahm F., Schrimpf D., Olar A., Kölsche C., Reuss D., Bissel J., Kratz A., Capper D., Schefzyk S., Hielscher T., Wang Q., Sulman E.P., Adeberg S., Koch A., Okuducu A.F., Brehmer S., Schittenhelm J., Becker A., Brokinkel B., Schmidt M., Ull T., Gousias K., Kessler F.A., Lamszus K., Debus J., Mawrin C., Kim Y.J., Simon M., Ketter R., Paulus W., Aldape K.D., Herold-Mende C., von Deimling A.: TERT promoter mutations and risk of recurrence in meningioma. J.Nat.Cancer Inst. 108 (5) djv377, 2016.

Sahm F., Schrimpf D., Jones D.T., Meyer J., Kratz A., Reuss D., Capper D., Kölsche C., Korshunov A., Wiestler B., Buchhalter I., Milde T., Selt F., Sturm D., Kool M., Hummel M., Bewerunge-Hudler M., Mawrin C., Schüller U., Jungk C., Wick A., Witt O., Platten M., Herold-Mende C., Unterberg A., Pfister S.M., Wick W., von Deimling A.: Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 131 (6) 903-910, 2016.

Schlenk R.F., Lübbert M., Benner A., Lamparter A., Krauter J., Herr W., Martin H., Salih H.R., Kündgen A., Horst H.A., Brossart P., Götze K., Nachbaur D., Wattad M., Köhne C.H., Fiedler W., Bentz M., Wulf G., Held G., Hertenstein B., Salwender H., Gaidzik V.I., Schlegelberger B., Weber D., Döhner K., Ganser A., Döhner H., German Austrian AML Study Group: All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. Ann.Hematol. 95 (12) 1931-1942, 2016.

Selt F., Deiss A., Korshunov A., Capper D., Witt H., van Tilburg C.M., Jones D.T., Witt R., Sahm F., Reuss D., Kölsche C., Ecker J., Öhme I., Hielscher T., von Deimling A., Kulozik A.E., Pfister S.M., Witt O., Milde T.: Pediatric targeted therapy: Clinical feasibility of personalized diagnostics in children with relapsed and progressive tumors. Brain Pathol. 26 (4) 506-516, 2016.

Sill M., Schröder C., Shen Y., Marzoq A., Komel R., Hoheisel J.D., Nienhüser H., Schmidt T., Kastelic D.: Protein profiling gastric cancer and neighboring control tissues using high-content antibody microarrays. Microarrays 5 (3) E19, 2016.

Sturm D., Orr B.A., Toprak U.H., Hovestadt V., Jones D.T., Capper D., Sill M., Buchhalter I., Northcott P.A., Leis I., Ryzhova M., Koelsche C., Pfaff E., Allen S.J., Balasubramanian G., Worst B.C., Pajtler K.W., Brabetz S., Johann P.D., Sahm F., Reimand J., Mackay A., Carvalho D.M., Remke M., Phillips J.J., Perry A., Cowdrey C., Drissi R., Fouladi M., Giangaspero F., Lastowska M., Grajkowska W., Scheurlen W., Pietsch T., Hagel C., Gojo J., Lötsch D., Berger W., Slavc I., Haberler C., Jouvet A., Holm S., Hofer S., Prinz M., Keohane C., Fried I., Mawrin C., Scheie D., Mobley B.C., Schniederjan M.J., Santi M., Buccoliero A.M., Dahiya S., Kramm C.M., Büren A.O.v., Hoff K.v., Rutkowski S., Herold-Mende C., Frühwald M.C., Milde T., Hasselblatt M., Wesseling P., Rößler J., Schüller U., Ebinger M., Schittenhelm J., Frank S., Grobholz R., Vajtai I., Hans V., Schneppenheim R., Zitterbart K., Collins V.P., Aronica E., Varlet P., Puget S., Dufour C., Grill J., Figarella-Branger D., Wolter M., Schuhmann M.U., Shalaby T., Grotzer M., Van Meter T., Monoranu C.M., Felsberg J., Reifenberger G., Snuderl M., Forrester L.A., Koster J., Versteeg R., Volckmann R., van Sluis P., Wolf S., Mikkelsen T., Gajjar A., Aldape K., Moore A.S., Tayler M.D., Jones C., Jabado N., Karajannis M.A., Eils R., Schlesner M., Lichter P., Deimling A.v., Pfister S.M., Ellison D.W., Korshunov A., Kool M.: New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell 164 (5) 1060-1072, 2016.

Tang Q., Holland-Letz T., Slynko A., Cuk K., Marme F., Schott S., Heil J., Qu B., Golatta M., Bewerunge-Hudler M., Sutter C., Surowy H., Wappenschmidt B., Schmutzler R., Hoth M., Bugert P., Bartram C.R., Sohn C., Schneeweiss A., Yang R., Burwinkel B.: DNA methylation array analysis identifies breast cancer associated - RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA. Oncotarget 7 (39) 64191-64202, 2016.

Thomas C., Sill M., Ruland V., Witten A., Hartung S., Kordes U., Jeibmann A., Beschorner R., Keyvani K., Bergmann M., Mittelbronn M., Pietsch T., Felsberg J., Monoranu C.M., Varlet P., Hauser P., Olar A., Grundy R.G., Wolf J.E., Korshunov A., Jones D.T., Bewerunge-Hudler M., Hovestadt V., Deimling A.v., Pfister S.M., Paulus W., Capper D., Hasselblatt M.: Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. Neuro-Oncol. 18 (6) 790-796, 2016.

Thompson E.M., Hielscher T., Bouffet E., Remke M., Luu B., Gururangan S., McLendon R.E., Bigner D.D., Lipp E.S., Perreault S., Cho Y.J., Grant G., Kim S.K., Lee J.Y., Rao A.A., Giannini C., Li K.K., Ng L.W., Yao Y., Kumabe T., Tominaga T., Grajkowska W.A., Perek-Polnik M., Low D.C., Seow W.T., Chang K.T., Mora J., Pollack I.F., Hamilton I.L., Leary S., Moore A.S., Ingram W.J., Hallahan A.R., Jouvet A., Fevre-Montange M., Vasiljevic A., Faure-Conter C., Shofuda T., Kagawa N., Hashimoto N., Jabado N., Weil A.G., Gayden T., Wataya T., Shalaby T., Grotzer M., Zitterbart K., Sterba J., Kren L., Hortobagyi T., Klekner A., Laszlo B., Pocza T., Hauser P., Schüller U., Jung S., Jang W.Y., French P.J., Kros J.M., van Veelen M.C., Massimi L., Leonard J.R., Rubin J.B., Vibhakar R., Chambless L.B., Cooper M.K., Thompson R.C., Faria C.C., Carvalho A., Nunes S., Pimentel J., Fan X., Muraszko K.M., Lopez-Aguilar E., Lyden D., Garzia L., Shih D.J., Kijima N., Schneider C., Adamski J., Northcott P.A., Kool M., Jones D.T., Chan J.A., Nikolic A., Garre M.L., Van Meir E.G., Osuka S., Olsen J.J., Jahangiri A., Castro B.A., Gupta N., Weiss W.A., Moxon-Emre I., Mabbott D.J., Lassaletta A., Hawkins C.E., Tabori U., Drake J., Kulkarni A., Dirks P., Rutka J.T., Korshunov A., Pfister S.M., Packer R.J., Ramaswamy V., Taylor M.D.: Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 17 (4) 484-495, 2016.

Viarisio D., Müller-Decker K., Kloz U., Aengeneyndt B., Kopp-Schneider A., Gröne H.J., Gheit T., Flechtenmacher C., Gissmann L., Tommasino M.: Correction: E6 and E7 from Beta Hpv38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS_PATHOG. 12 (10) e1006005, 2016.

Weber C.E., Luo C., Hotz-Wagenblatt A., Gardyan A., Kordass T., Holland-Letz T., Osen W., Eichmüller S.B.: miR-339-3p Is a tumor suppressor in melanoma. Cancer Res. 76 (12) 3562-3571, 2016.

Weigel C., Veldwijk M.R., Oakes C.C., Seibold P., Slynko A., Liesenfeld D.B., Rabionet M., Hanke S.A., Wenz F., Sperk E., Benner A., Rösli C., Sandhoff R., Assenov Y., Plass C., Herskind C., Chang-Claude J., Schmezer P., Popanda O.: Epigenetic regulation of diacylglycerol kinase alpha promotes radiation-induced fibrosis. Nat.Commun. 7 (Article No. 10893) , 2016.

Weinhold N., Kirn D., Seckinger A., Hielscher T., Granzow M., Bertsch U., Egerer G., Salwender H., Blau I.W., Weisel K., Hillengass J., Raab M.S., Hose D., Goldschmidt H., Jauch A.: Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica 101 (3) e116-e119, 2016.

Zhan T., Hielscher T., Hahn F., Hauf C., Betge J., Ebert M.P., Belle S.: Risk factors for local recurrence of large, flat colorectal polyps after endoscopic mucosal resection. Digestion 93 (4) 311-317, 2016.

to top
powered by webEdition CMS